Clinical Report: Metabolic and Epigenetic Changes in Rheumatoid Arthritis
Overview
This review elucidates the metabolic and epigenetic alterations in rheumatoid arthritis (RA) that contribute to persistent pathogenic memory, complicating treatment outcomes. It highlights the role of metabolic byproducts as epigenetic regulators that reinforce inflammatory phenotypes in immune cells.
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to significant joint damage and disability. Despite advancements in treatment, achieving sustained drug-free remission remains challenging due to the persistence of pathogenic memory within the joint microenvironment. Understanding the metabolic and epigenetic mechanisms underlying this persistence is crucial for developing more effective therapeutic strategies.
Data Highlights
No specific numerical data or trial results are presented in the article.
Key Findings
RA is characterized by a hostile synovial microenvironment that induces metabolic reprogramming in immune cells.
Accumulation of metabolites like lactate and acetyl-CoA serves as epigenetic regulators, altering chromatin architecture.
Aberrant post-translational modifications (PTMs) such as lactylation and acetylation contribute to the persistence of inflammatory phenotypes.
Hyperactive acetyltransferases and reduced Sirtuin activity lead to resilient epigenetic scars in immune cells.
The gut-microbiota-joint axis and chronobiological rhythms play a role in the systemic regulation of RA.
Clinical Implications
Clinicians should consider the metabolic and epigenetic factors contributing to RA pathogenesis when developing treatment plans. Targeting these pathways may offer new avenues for achieving sustained remission and improving patient outcomes.
Conclusion
The integration of metabolic and epigenetic insights into RA pathogenesis presents opportunities for innovative therapeutic approaches that go beyond conventional immunosuppression.
